AleAnna, Inc. (ANNA)

NASDAQ: ANNA · Real-Time Price · USD
11.50
0.00 (0.00%)
Jan 22, 2025, 10:51 AM EST - Market open
0.00%
Market Cap 765.38M
Revenue (ttm) 648,328
Net Income (ttm) -162.45M
Shares Out 66.55M
EPS (ttm) -609.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,511
Open 11.40
Previous Close 11.50
Day's Range 11.36 - 11.50
52-Week Range 5.82 - 18.70
Beta 0.20
Analysts n/a
Price Target n/a
Earnings Date n/a

About ANNA

AleAnna, Inc., a natural gas resource company, focuses on delivering critical natural gas supplies in Italy. It operates through onshore conventional natural gas exploration and renewable natural gas development. The company was founded in 2007 and is headquartered in Dallas, Texas. [Read more]

Founded 2007
Country United States
Stock Exchange NASDAQ
Ticker Symbol ANNA
Full Company Profile

Financial Performance

Financial Statements

News

AleAnna Announces Signing of Gas Sale Contract with Shell Energy Europe

AleAnna Secures A Contract To Sell Its Gas To Shell Energy Europe Ltd, A Leading Natural Gas, Power And Environmental Trading Company Across European Markets AleAnna has signed a multi-year gas sales ...

4 weeks ago - GlobeNewsWire

AleAnna, Inc. Announces Completion of Several Major Milestones for its Renewable Natural Gas (RNG) Business

DALLAS and ROME, Dec. 18, 2024 (GLOBE NEWSWIRE) -- AleAnna, Inc., (“AleAnna” or the “Company”) (Nasdaq: ANNA), today announced the completion of a series of initiatives through which the Company has e...

5 weeks ago - GlobeNewsWire

BRS Resources Announces Update on AleAnna Energy, LLC

Vancouver, British Columbia--(Newsfile Corp. - December 16, 2024) - BRS RESOURCES LTD. (CSE: BRS) (the "Company" or "BRS"), a mineral exploration company, is pleased to provide an update on its member...

5 weeks ago - Newsfile Corp

HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.

NEW YORK & VERO BEACH, Fla.--(BUSINESS WIRE)---- $ipo #Consumer--HDL Therapeutics, Inc. (“HDL Therapeutics”), a privately held commercial stage biotech company with an FDA-approved cardiovascular ther...

1 year ago - Business Wire

HDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination With $225 Million Swiftmerge (NASDAQ: IVCP) With Goal to Transform Cardiovascular Disease Treatment

NEW YORK & VERO BEACH, Fla.--(BUSINESS WIRE)---- $health #Consumer--NASDAQ IVCP Swiftmerge Acquisition Corp (“Swiftmerge”), a $225 million innovative healthcare investment corporation and a special pu...

1 year ago - Business Wire